A Study of LY2127399 in Patients with Systemic Lupus Erythematosus

The purpose of this SLE study is to evaluate the efficacy, safety and tolerability of two different doses of LY2127399 administered in addition to standard of care therapy in patients with active SLE.

Official Title

A Phase 3, Multicenter, Randomised, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)

Conditions

Systemic Lupus Erythematosus
Connective Tissue Disease
Autoimmune Disease

Study Type

Interventional

Study Design

Allocation: Randomised
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Further Details

Primary Outcome Measures:

• Proportion of patients achieving an SLE Responder Index response at week 5

 

Secondary Outcome Measures:

• Proportion of patients able to decrease dose of prednisone or equivalent with no increase in disease activity at week 52

• Change from baseline to 52 weeks in anti-double stranded deoxyribonucleic acid (anti-dsDNA) level [ Time Frame: Baseline, 52 weeks ] [ Designated as safety issue: No ]
• Change from baseline to 52 week endpoint in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI2K) score [ Time Frame: Baseline, 52 weeks ] [ Designated as safety issue: No ]
• Time to first severe SLE flare (SFI) [ Time Frame: Baseline through 52 weeks ] [ Designated as safety issue: No ]
• Change from baseline to 52 week endpoint in Physician’s Global Assessment (PGA) [ Time Frame: Baseline, 52 weeks ] [ Designated as safety issue: No ]
• Change from baseline to 52 week endpoint Lupus Quality of Life (LupusQOL) composite and domain scores [ Time Frame: Baseline, 52 weeks ] [ Designated as safety issue: No ]
• Proportion of patients with no worsening in Physician Global Assessment (PGA) score at 52 weeks [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
• Change from baseline to 52 week endpoint in Brief Fatigue Inventory (BFI) scores [ Time Frame: Baseline, 52 weeks ] [ Designated as safety issue: No ]
• Time to first new British Isles Lupus Assessment Group (BILAG A) or 2 new BILAG B SLE flares [ Time Frame: Baseline through 52 weeks ] [ Designated as safety issue: No ]
• Proportion of patients with an increase in corticosteroids dose at 52 weeks [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
• Change from baseline to 52 weeks endpoint in Safety of Estrogens in Lupus Erythematosus National Assessment- Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) disease activity score [ Time Frame: Baseline, 52 weeks ] [ Designated as safety issue: No ]
• Change from baseline to 52 week endpoint BILAG numeric scores [ Time Frame: Baseline, 52 weeks ] [ Designated as safety issue: No ]
• Proportion of patients achieving a response as measured by modified SLE Responder Index (SRI) with no BILAG A or no more than 1 BILAG B organ domain flares at 52 weeks [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]

Study Start

January 2011 – February 2014

Eligibility & Criteria

Ages Eligible for Study: 18 Years and older

Genders Eligible for Study: Both

Accepts Healthy Volunteers: No

 

Criteria

Inclusion Criteria:

• Clinical diagnosis of SLE as defined by American College of Rheumatology (ACR) criteria
• Have positive antinuclear antibodies (ANA)
• Agree not to become pregnant throughout the course of the trial
• Have the appropriate Safety of Estrogens in Lupus Erythematosus National Assessment – Systemic Lupus Erythematosus (SLE) Disease Activity Index (SELENA-SLEDAI) score at screening

 

Exclusion Criteria:

• Have active severe Lupus kidney disease
• Have active Central Nervous System or peripheral neurologic disease
• Have received intravenous immunoglobulin (IVIg) within 180 days of randomisation
• Have active or recent infection within 30 days of screening
• Have had a serious infection within 90 days of randomisation
• Have evidence or test positive for Hepatitis B
• Have Hepatitis C
• Are human immunodeficiency virus (HIV) positive
• Have evidence of active or latent tuberculosis (TB)
• Presence of significant laboratory abnormalities at screening
• Have had a malignancy in the past 5 years, except for cervical carcinoma in-situ or basal cell or squamous epithelial skin cell that were completely resected with no reoccurrence in the 3 yrs prior to randomization
• Have received greater than 40 mgs of prednisone or equivalent in the past 30 days
• Have changed your dose of antimalarial drug in the past 30 days
• Have changed your dose of immunosuppressive drug in the past 90 days
• Have previously received rituximab

Total Enrolment

1140

Contact Details

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon – Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST),